Featured

VISION – An insightful Q&A series with Orrbitt’s Founder & Creative Director

“The future is something we can’t see..not yet at least. In a creative space, we can track trends and plot where we think we’re headed but if I’ve learned anything about art, it’s that it refuses to be controlled or fully understood. I’m along for the ride.. and so is Orrbitt.”

Learn More
Projects

Orrbitt Launches METEORR – Life Science’s First and Only Design Shop

METEORR is a one-stop-shop for biotech companies wanting to create a cohesive and high-end corporate look. With METEORR you can choose from a full range of branded materials including websites, PowerPoint decks, and brand collateral all in one place.

Learn More
Design

Orrbitt’s Process for How Business Cards Get Done

The design approval is just one step of the process – with obviously the end goal being a printed card for designated members of your team. In our experience, there are 3 typical processes that work in order to get from design approval to printed cards.

Learn More
Design

Content Hierarchy in Biotech Websites

Content hierarchy is about how your content is organized and presented. Most web users only spend seconds scanning a page for something of interest before giving up. A story that is easy to navigate and understand is a good indicator that the story is also strong and compelling.

Learn More
Client Advice

How to Use InVision for Reviewing Your Designs

InVision is an online application that allows Orrbitt to share and review design mockups. You are able to view mockups and leave comments simply by clicking on the area of the design in question.

Learn More
Client Advice

Revision Rounds: What Are They and How Can You Take Advantage Of Them?

Revision rounds are one of the most important aspects of a design project. It’s where you, the client, get to…

Learn More
Projects

Orrbitt Launches Proneurotech’s New Landing Page

Proneurotech is a biopharmaceutical company backed by The Column Group focused on discovering and developing neuroprotective drugs that prevent axon loss after acute injury or chronic degenerative disease.

Learn More